SciClone Pharmaceuticals (SCLN) Shares are Up 3.67%

SciClone Pharmaceuticals (SCLN) : Traders are bullish on SciClone Pharmaceuticals (SCLN) as it has outperformed the S&P 500 by a wide margin of 5.08% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 3.12%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 3.67% in the last 1 week, and is up 2.95% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 2.1% and the 50-Day Moving Average is 3.62%.The 200 Day SMA reached 3.29% SciClone Pharmaceuticals, Inc. has dropped 22.46% during the last 3-month period . Year-to-Date the stock performance stands at 13.7%.


The shares have received a consensus rating of Sell for the current week SciClone Pharmaceuticals (NASDAQ:SCLN): The stock opened at $10.31 and touched an intraday high of $10.63 on Friday. During the day, the stock corrected to an intraday low of $10.09, however, the bulls stepped in and pushed the price higher to close in the green at $10.46 with a gain of 1.85% for the day. The total traded volume for the day was 1,060,765. The stock had closed at $10.46 in the previous trading session.

SciClone Pharmaceuticals Inc. (SciClone) is a pharmaceutical company. The Company operates in two geographic segments, including China and the rest of the world (the United States and Hong Kong). The Companys lead product ZADAXIN (thymalfasin) is used for the treatment of hepatitis B virus (HBV) hepatitis C (HCV) as a vaccine adjuvant and certain cancers. Its development portfolio includes Angiomax, an anticoagulant indicated in patients undergoing percutaneous coronary intervention (PCI); Neucardin, therapeutic drug for the treatment of patients with intermediate to advanced chronic heart failure (CHF); Loramyc, a mucoadhesive tablet formulation of miconazole lauriad to treat oropharyngeal candidiasis; Cleviprex, a third-generation dihydropyridine calcium channel blocker for the reduction of blood pressure; ProFlow to treat peripheral arterial disease (PAD) and other indications, and RapidFilm, an oral film formulation of ondansetron to treat nausea induced by chemotherapy.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.